Healthcare provider profile · identity verified

Kip Alan Corrington, MD

Allopathic & Osteopathic Physicians|Family Medicine · OAK RIDGE, NC · NPI 1215049242

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kip Alan Corrington, MD received $124.61 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$124.61

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$124.61	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$124.61	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$124.61	1	2025
Source payment records 2025-08-27 · Lilly USA, LLC · $124.61 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	74	11
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	24	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	325	90
Amlodipine Besylate	Amlodipine Besylate	245	79
Levothyroxine Sodium	Levothyroxine Sodium	221	59
Lisinopril	Lisinopril	206	64
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	186	34
Omeprazole	Omeprazole	171	46
Gabapentin	Gabapentin	169	42
Alprazolam	Alprazolam	166	33
Rosuvastatin Calcium	Rosuvastatin Calcium	145	43
Hydrochlorothiazide	Hydrochlorothiazide	141	38
Albuterol Sulfate Hfa	Albuterol Sulfate	135	36
Tamsulosin Hcl	Tamsulosin Hcl	126	33
Trazodone Hcl	Trazodone Hcl	125	30
Metformin Hcl Er	Metformin Hcl	120	36
Metoprolol Succinate	Metoprolol Succinate	116	35
Pantoprazole Sodium	Pantoprazole Sodium	111	35
Metformin Hcl	Metformin Hcl	109	30
Olmesartan Medoxomil	Olmesartan Medoxomil	107	35
Simvastatin	Simvastatin	94	26
Furosemide	Furosemide	91	28
Losartan Potassium	Losartan Potassium	91	26
Allopurinol	Allopurinol	89	25
Farxiga	Dapagliflozin Propanediol	87	15
Sertraline Hcl	Sertraline Hcl	87	20
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	83	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	21
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	77	21
Carvedilol	Carvedilol	75	23
Fluoxetine Hcl	Fluoxetine Hcl	74	14
Jardiance	Empagliflozin	74	11
Clopidogrel	Clopidogrel Bisulfate	72	19
Pravastatin Sodium	Pravastatin Sodium	70	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	68	19
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	68	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	67	suppressed
Potassium Chloride	Potassium Chloride	66	19
Bupropion Xl	Bupropion Hcl	65	16
Clonazepam	Clonazepam	65	15
Meloxicam	Meloxicam	63	15
Pregabalin	Pregabalin	60	12
Diazepam	Diazepam	59	14
Ozempic	Semaglutide	59	13
Escitalopram Oxalate	Escitalopram Oxalate	56	16
Montelukast Sodium	Montelukast Sodium	56	19
Buprenorphine Hcl	Buprenorphine Hcl	53	suppressed
Ropinirole Hcl	Ropinirole Hcl	52	11
Fluticasone Propionate	Fluticasone Propionate	50	22
Famotidine	Famotidine	49	16
Xarelto	Rivaroxaban	44	suppressed
Duloxetine Hcl	Duloxetine Hcl	43	suppressed
Tizanidine Hcl	Tizanidine Hcl	42	suppressed
Finasteride	Finasteride	41	11
Tramadol Hcl	Tramadol Hcl	41	13
Eliquis	Apixaban	40	13
Metoprolol Tartrate	Metoprolol Tartrate	40	14
Sumatriptan Succinate	Sumatriptan Succinate	39	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	38	13
Ezetimibe	Ezetimibe	37	11
Citalopram Hbr	Citalopram Hydrobromide	36	12
Fenofibrate	Fenofibrate	35	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	31	14
Linzess	Linaclotide	31	suppressed
Lorazepam	Lorazepam	31	14
Oxycodone Hcl	Oxycodone Hcl	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Ondansetron Hcl	Ondansetron Hcl	29	13
Tresiba Flextouch U-100	Insulin Degludec	29	suppressed
Alendronate Sodium	Alendronate Sodium	28	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	22
Ibuprofen	Ibuprofen	26	suppressed
Prednisone	Prednisone	26	19
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Topiramate	Topiramate	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	18
Mounjaro	Tirzepatide	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	16
Aimovig Autoinjector	Erenumab-Aooe	19	suppressed
Cephalexin	Cephalexin	19	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Suboxone	Buprenorphine Hcl/Naloxone Hcl	19	suppressed
Eszopiclone	Eszopiclone	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Promethazine Hcl	Promethazine Hcl	18	suppressed
Rybelsus	Semaglutide	18	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Terbinafine Hcl	Terbinafine Hcl	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Baclofen	Baclofen	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Colchicine	Colchicine	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Glipizide	Glipizide	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Amoxicillin	Amoxicillin	14	13
Benazepril Hcl	Benazepril Hcl	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Torsemide	Torsemide	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Testosterone	Testosterone	12	suppressed
Valsartan	Valsartan	12	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Zubsolv	Buprenorphine Hcl/Naloxone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$124.61 · 1 records	Lilly USA, LLC	ZEPBOUND	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error